| Inhaled treprostinil for the treatment of pulmonary arterial hypertension. | |
| | |
MedLine Citation:
|
PMID: 22135338 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pulmonary arterial hypertension is a progressive disease characterized by vascular proliferation and vasoconstriction of the small pulmonary arteries that eventually leads to right-sided heart failure and death. Patients often initially have symptoms such as shortness of breath, fatigue, and edema; later in the disease, presyncope and syncope are common. Patients with progressive pulmonary arterial hypertension despite oral therapy and/or with severe disease typically require treatment with a prostanoid. Inhaled treprostinil (Tyvaso) is a prostacyclin analog indicated for the treatment of pulmonary arterial hypertension to increase walk distance in patients with symptoms classified as New York Heart Association functional class III. Inhaled treprostinil was approved by the Food and Drug Administration in July 2009. This article provides a brief overview of the pathophysiology of pulmonary arterial hypertension and reviews the mechanism of action, key clinical data, and the practical management of inhaled treprostinil in patients with pulmonary arterial hypertension. |
| | |
Authors:
|
Abby Poms; Martha Kingman |
Related Documents
:
|
22015568 - 2009 esc/ers pulmonary hypertension guidelines and connective tissue disease. 21914448 - C-122, a novel antagonist of serotonin receptor 5-ht(2b), prevents monocrotaline-induce... 22035778 - Mechanisms of pulmonary hypertension related to ventricular septal defect in congenital... 10347258 - Cryopreserved arterial homografts: preliminary results in infrageniculate arterial reco... 18727978 - Heavily calcified chronic total occlusion of common iliac artery successfully treated w... 937058 - Effect of lung irradiation on the incidence of pulmonary metastases and its mechanism. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Critical care nurse Volume: 31 ISSN: 1940-8250 ISO Abbreviation: Crit Care Nurse Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-02 Completed Date: 2012-04-26 Revised Date: 2012-05-14 |
Medline Journal Info:
|
Nlm Unique ID: 8207799 Medline TA: Crit Care Nurse Country: United States |
Other Details:
|
Languages: eng Pagination: e1-10 Citation Subset: N |
Affiliation:
|
Duke University Medical Center, Durham, North Carolina 27710, USA. krich001@mc.duke.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Inhalation Antihypertensive Agents / administration & dosage* Epoprostenol / administration & dosage, analogs & derivatives* Humans Hypertension, Pulmonary / drug therapy*, physiopathology Medical Illustration Randomized Controlled Trials as Topic Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/treprostinil; 35121-78-9/Epoprostenol |
| Comments/Corrections | |
Erratum In:
|
Crit Care Nurse. 2012 Apr;32(2):11 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Using a nursing productivity committee to achieve cost savings and improve staffing levels and staff...
Next Document: Critical care staff nurses: empowerment, certification, and intent to leave.